|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.25 GBX | -2.99% |
|
-23.53% | -76.79% |
| Apr. 25 | Norcros sells Johnson Tiles UK; Trifast trading well | AN |
| Apr. 25 | Transcript : Destiny Pharma plc, 2023 Earnings Call, Apr 25, 2024 |
(via NewsDirect)
Clark says that Destiny Pharma is focused on finding a partner for its lead asset, XF-73, a nasal gel that decolonizes patients before surgery to prevent post-surgical infections.
He adds that the asset is now "very well positioned" for a partnering programme.
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source
| 1st Jan change | Capi. | |
|---|---|---|
| -76.79% | 19.29M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
DESTINY PHARMA PLC 
